MetaCap

Kailera Therapeutics Insider Trades

NASDAQ: KLRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

11.02-0.56 (-4.84%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
5 · $326.75M
Sales
0 · $0
Shares bought / sold
20.42M / 0
Net activity
Net buying $326.8 million

Kailera Therapeutics insider activity

Over the last 12 months, Kailera Therapeutics insiders reported 15 transactions on SEC Form 4: 5 open-market purchases and 0 sales. Insiders bought $326.8 million and sold $0 worth of stock, for net insider buying of $326.8 million. The most recent filing shows Renaud Ronald C JR (CEO & President) reporting a transaction in 38,094 shares at $5.25 on Jun 9, 2026.

Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put KLRA's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

KLRA insider transactions

Kailera Therapeutics insider transactions
DateInsiderTypeSharesValueFiling
Jun 9, 2026Renaud Ronald C JRCEO & PresidentOption exercise38,094$199.99KForm 4
Apr 20, 2026Kaplan Andrew T.DirectorBuy8,398,438$134.38MForm 4
Apr 20, 2026Kaplan Andrew T.DirectorConversion17,857,143—Form 4
Apr 20, 2026Bain Capital Life Sciences Investors, LLC & Bain Capital Life Sciences IV General Partner, LLC & Bain Capital Life Sciences Fund IV, L.P. & BCLS Fund IV Investments GP, LLC & BCLS Fund IV Investments, L.P.10% OwnerBuy1,562,500$25.00MForm 4
Apr 20, 2026Bain Capital Life Sciences Investors, LLC & Bain Capital Life Sciences IV General Partner, LLC & Bain Capital Life Sciences Fund IV, L.P. & BCLS Fund IV Investments GP, LLC & BCLS Fund IV Investments, L.P.10% OwnerConversion4,145,768—Form 4
Apr 20, 2026Bain Capital Life Sciences Investors, LLC & Bain Capital Life Sciences IV General Partner, LLC & Bain Capital Life Sciences Fund IV, L.P. & BCLS Fund IV Investments GP, LLC & BCLS Fund IV Investments, L.P.10% OwnerConversion16,875,000—Form 4
Apr 20, 2026Koppel AdamDirectorBuy1,562,500$25.00MForm 4
Apr 20, 2026Koppel AdamDirectorConversion4,145,768—Form 4
Apr 20, 2026Koppel AdamDirectorConversion16,875,000—Form 4
Apr 20, 2026BAIN CAPITAL INVESTORS LLC & Bain Capital XIV General Partner, LLC & Bain Capital Fund XIV, L.P. & BCPE Perseus Investor GP, LLC & BCPE Perseus Investor, LP10% OwnerBuy8,398,438$134.38MForm 4
Apr 20, 2026BAIN CAPITAL INVESTORS LLC & Bain Capital XIV General Partner, LLC & Bain Capital Fund XIV, L.P. & BCPE Perseus Investor GP, LLC & BCPE Perseus Investor, LP10% OwnerConversion17,857,143—Form 4
Apr 20, 2026RTW INVESTMENTS, LP & WONG RODERICK10% OwnerBuy500,000$8.00MForm 4
Apr 20, 2026RTW INVESTMENTS, LP & WONG RODERICK10% OwnerConversion10,276,820—Form 4
Apr 20, 2026Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% OwnerConversion2,034,133—Form 4
Apr 20, 2026Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% OwnerConversion9,477,719—Form 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related